Pregnancy Testing Requirements for Isotretinoin
Yes, pregnancy testing is absolutely mandatory for all patients of childbearing potential before starting isotretinoin and must be repeated monthly throughout treatment. This is a non-negotiable requirement established by both FDA regulations and current clinical guidelines 1.
Specific Testing Protocol
The FDA-mandated iPLEDGE REMS program requires the following pregnancy testing algorithm for patients who can become pregnant 1:
Before Starting Treatment
- Two negative pregnancy tests required with sensitivity of at least 25 mIU/mL
- First test (screening): Obtained when the decision is made to prescribe isotretinoin
- Second test (confirmation): Must be done in a CLIA-certified laboratory, at least 19 days after the first test
Timing of the second test depends on menstrual status:
- Regular cycles: Test during the first 5 days of the menstrual period immediately before starting isotretinoin, after using two forms of contraception for one month
- Amenorrhea/irregular cycles: Test immediately before starting isotretinoin, after using two forms of contraception for one month
During Treatment
- Monthly negative pregnancy test required in a CLIA-certified laboratory before each prescription refill 1
After Treatment
- Pregnancy test at completion of therapy
- Another pregnancy test one month after the last dose 1
Rationale: The Teratogenic Risk
The 2024 American Academy of Dermatology guidelines explicitly state: "For persons of childbearing potential, pregnancy prevention is mandatory" 2. This stems from isotretinoin's severe teratogenic effects:
- Historical data shows 48% of exposed pregnancies resulted in congenital malformations 3
- 28% of prospectively followed pregnancies ending in birth had congenital malformations 3
- Exposure during any time in the first trimester, even for as little as one capsule, has been associated with malformations 3
- 33% of exposed women were already pregnant when starting isotretinoin, and another 16% became pregnant within the first 3 weeks of use 3
Critical Pitfalls to Avoid
Do not skip the second confirmatory test. The requirement for two tests exists because 33% of women in one study were already pregnant when initiating therapy 3. The 19-day interval between tests ensures detection of very early pregnancy.
Do not accept non-CLIA certified tests for the confirmatory or monthly tests. While the initial screening can be a standard pregnancy test, all subsequent tests must be CLIA-certified 1.
Do not prescribe to males or postmenopausal women without pregnancy testing. These populations are exempt from pregnancy testing requirements but still require enrollment in iPLEDGE 1.
For Non-Childbearing Patients
Patients who cannot become pregnant (males, postmenopausal women, those with documented hysterectomy or bilateral oophorectomy) do not require pregnancy testing but must still be enrolled in the iPLEDGE program 1.